CTT Pharma Reduces Authorized Share Count
Rhea-AI Summary
CTT Pharmaceuticals Holdings (OTC:CTTH) has announced a significant reduction in its authorized share count, cutting it by 150 million shares from 300 million to 150 million shares. The change has been officially filed with the Delaware Division of Corporations and recorded by the company's stock issuer.
The company states this adjustment reflects its commitment to optimizing its capital structure and creating long-term shareholder value. Additionally, CTT is pursuing approval for an uplisting to the OTCQB market.
Positive
- Reduction of authorized shares by 50% (from 300M to 150M shares)
- Pursuing uplisting to OTCQB from OTC markets
Negative
- None.
News Market Reaction
On the day this news was published, CTTH gained 8.07%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
TAMPA, FL / ACCESS Newswire / February 3, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC:CTTH) is pleased to announce a reduction in its authorized share count by 150 million shares. CTT reduced the authorized share count from 300 million shares to 150 million shares. This change has already been filed with Delaware Division of Corporations. Furthermore, CTT's stock issuer has been notified and made the necessary corrections to reflect this change. This latest adjustment demonstrates CTT Pharma's ongoing commitment to optimizing its capital structure and delivering long-term value to shareholders. CTT is also in the process of gaining approval to uplist to the OTCQB and believes this decision benefits existing and future shareholders.
About CTT Pharmaceuticals Holdings, Inc.
CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
Investor Relations - 813-606-0060
SOURCE: CTT Pharmaceuticals Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
How many shares did CTT Pharmaceuticals (CTTH) reduce from its authorized share count in February 2025?
What is the new authorized share count for CTT Pharmaceuticals (CTTH)?
Which exchange is CTT Pharmaceuticals (CTTH) planning to uplist to?
How does the share reduction benefit CTTH shareholders?
